Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 169 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2014', provides an overview of the Cytomegalovirus (HHV-5) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cytomegalovirus (HHV-5) Infections Overview 8
Therapeutics Development 9
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 9
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 10
Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 11
Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 15
Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 21
Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 23
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 24
Vical Incorporated 24
GlaxoSmithKline plc 25
Genentech, Inc. 26
Agenus, Inc. 27
Biotest AG 28
Merck & Co., Inc. 29
Astellas Pharma Inc. 30
4SC AG 31
Bionor Pharma ASA 32
Altor BioScience Corporation 33
Phoenix Biotechnology, Inc. 34
Cell Medica Limited 35
AlphaVax, Inc. 36
Chimerix, Inc. 37
Theraclone Sciences, Inc. 38
Microbiotix, Inc. 39
VBI Vaccines 40
AIMM Therapeutics B.V. 41
Trellis Bioscience, Inc. 42
Vakzine Projekt Management GmbH 43
Spider Biotech 44
INAGEN ApS 45
Applied Immune Technologies Ltd 46
Redbiotec AG 47
Conkwest, Inc. 48
Hookipa Biotech AG 49
Kadmon Corporation, LLC 50
Humabs BioMed SA 51
BioApex, s.r.o. 52
CAP-CMV GmbH 53
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 66
brincidofovir - Drug Profile 66
ASP-0113 - Drug Profile 68
letermovir - Drug Profile 69
Cytovir CMV - Drug Profile 70
BT-094 - Drug Profile 72
maribavir - Drug Profile 73
TCN-202 - Drug Profile 75
Cell Therapy Targeting PP65 for Cytomegalovirus Infections - Drug Profile 76
RG-7667 - Drug Profile 77
Cell Therapy for Infectious Diseases - Drug Profile 78
Cell Therapy Targeting PP65 for Cytomegalovirus Infections - Drug Profile 79
Gene Therapy for Cytomegalovirus Infection - Drug Profile 80
Cell Therapy for CMV Infections - Drug Profile 81
AVX-601 - Drug Profile 82
Cell Therapy for Cytomegalovirus Infections and GBM - Drug Profile 84
Cell Therapy for Cytomegalovirus Infections - Drug Profile 85
Vaccine for Cytomegalovirus Infections - Drug Profile 86
Cell Therapy for CMV Infection - Drug Profile 87
filociclovir - Drug Profile 88
Cell Therapy for Infectious Disease - Drug Profile 90
Small Molecule 1 for Human Cytomegalovirus Infection - Drug Profile 91
Small Molecule 2 for Human Cytomegalovirus Infection - Drug Profile 92
MAb Against HCMV - Drug Profile 93
Gene Therapy for Cytomegalovirus Infections - Drug Profile 94
cytomegalovirus vaccine - Drug Profile 95
Cell Therapy for Cytomegalovirus Infections - Drug Profile 96
V-160 - Drug Profile 97
CyMVectin - Drug Profile 98
Antiviral TCR-Ck - Drug Profile 99
Antiviral TCR-Ig - Drug Profile 100
4Ab-028 - Drug Profile 101
CST-102 - Drug Profile 102
VPM-2001 - Drug Profile 103
RBT-301 - Drug Profile 104
VBI-1501A - Drug Profile 105
TRL-345 - Drug Profile 106
SB-105 - Drug Profile 107
Monoclonal Antibody for Cytomegalo Virus Infections - Drug Profile 108
HB-101 - Drug Profile 109
Drug For Cytomegalovirus - Drug Profile 110
Small Molecule 3 for Human Cytomegalovirus Infection - Drug Profile 111
Dual Active Cytomegalovirus (CMV)/Polyomavirus BK (BKV) Program - Drug Profile 112
4SC-302 - Drug Profile 113
Cell Therapy for Cytomegalovirus Infections - Drug Profile 114
Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 115
BA-368 - Drug Profile 116
CAP-CMV-001 - Drug Profile 117
RKP-00156 - Drug Profile 118
Monoclonal Antibody for Infectious Diseases - Drug Profile 119
Small Molecules to Inhibit Cyclophilins - Drug Profile 120
Antibody Targeting HLA-A2 for Cytomegalovirus Infections - Drug Profile 122
Small Molecules for Viral Infections - Drug Profile 123
SB105-A10 - Drug Profile 124
AL-18 - Drug Profile 126
Protein For Cytomegalovirus Infections - Drug Profile 127
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 128
Vaccine for Cytomegalovirus (CMV) Infection - Drug Profile 129
Vacc-CMV - Drug Profile 130
Cell Therapy 3 For CMV - Drug Profile 131
Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates 132
Cytomegalovirus (HHV-5) Infections - Dormant Projects 150
Cytomegalovirus (HHV-5) Infections - Discontinued Products 151
Cytomegalovirus (HHV-5) Infections - Product Development Milestones 152
Featured News & Press Releases 152
Appendix 163
Methodology 163
Coverage 163
Secondary Research 163
Primary Research 163
Expert Panel Validation 163
Contact Us 164
Disclaimer 164

List of Tables
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2014 14
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Development by Companies, H2 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2014 21
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Development, H2 2014 24
Comparative Analysis by Unknown Stage Development, H2 2014 25
Products under Development by Companies, H2 2014 26
Products under Development by Companies, H2 2014 (Contd..1) 27
Products under Investigation by Universities/Institutes, H2 2014 28
Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Incorporated, H2 2014 29
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline plc, H2 2014 30
Cytomegalovirus (HHV-5) Infections - Pipeline by Genentech, Inc., H2 2014 31
Cytomegalovirus (HHV-5) Infections - Pipeline by Agenus, Inc., H2 2014 32
Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H2 2014 33
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co., Inc., H2 2014 34
Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc., H2 2014 35
Cytomegalovirus (HHV-5) Infections - Pipeline by 4SC AG, H2 2014 36
Cytomegalovirus (HHV-5) Infections - Pipeline by Bionor Pharma ASA, H2 2014 37
Cytomegalovirus (HHV-5) Infections - Pipeline by Altor BioScience Corporation, H2 2014 38
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology, Inc., H2 2014 39
Cytomegalovirus (HHV-5) Infections - Pipeline by Cell Medica Limited, H2 2014 40
Cytomegalovirus (HHV-5) Infections - Pipeline by AlphaVax, Inc., H2 2014 41
Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix, Inc., H2 2014 42
Cytomegalovirus (HHV-5) Infections - Pipeline by Theraclone Sciences, Inc., H2 2014 43
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix, Inc., H2 2014 44
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines, H2 2014 45
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics B.V., H2 2014 46
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience, Inc., H2 2014 47
Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H2 2014 48
Cytomegalovirus (HHV-5) Infections - Pipeline by Spider Biotech, H2 2014 49
Cytomegalovirus (HHV-5) Infections - Pipeline by INAGEN ApS, H2 2014 50
Cytomegalovirus (HHV-5) Infections - Pipeline by Applied Immune Technologies Ltd, H2 2014 51
Cytomegalovirus (HHV-5) Infections - Pipeline by Redbiotec AG, H2 2014 52
Cytomegalovirus (HHV-5) Infections - Pipeline by Conkwest, Inc., H2 2014 53
Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H2 2014 54
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corporation, LLC, H2 2014 55
Cytomegalovirus (HHV-5) Infections - Pipeline by Humabs BioMed SA, H2 2014 56
Cytomegalovirus (HHV-5) Infections - Pipeline by BioApex, s.r.o., H2 2014 57
Cytomegalovirus (HHV-5) Infections - Pipeline by CAP-CMV GmbH, H2 2014 58
Assessment by Monotherapy Products, H2 2014 59
Number of Products by Stage and Target, H2 2014 62
Number of Products by Stage and Mechanism of Action, H2 2014 65
Number of Products by Stage and Route of Administration, H2 2014 67
Number of Products by Stage and Molecule Type, H2 2014 70
Cytomegalovirus (HHV-5) Infections Therapeutics - Recent Pipeline Updates, H2 2014 137
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2014 155
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H2 2014 156